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Abstract: We aimed to compare clinical characteristics between Asian and Western
chronic obstructive pulmonary disease (COPD) patients. This was a sub-analysis of an
international, multicenter, prospective cohort study. Asian patients were enrolled in
Singapore and South Korea. Western patients were enrolled in Spain, Poland, Ireland,
the United Kingdom, and Malta. A total of 349 patients were analyzed. Among them,
110 (32%) patients were Asian and 239 (68%) Western. Male sex was more predomi-
nant in Asian than in Western (95% versus 63%, respectively; P<0.01). Body mass
index was significantly lower in Asian (23.5 versus 27.1; P<0.01). The proportion of
patients with a history of exacerbation was lower in Asian (12% versus 64%; P<0.01).
Although patients were enrolled by same inclusion criteria, there were several differ-
ences between Asian and Western COPD patients. Our study has shown unbiased real-
world differences between Asian and Western COPD patients. Since prospective fol-
low-up study is currently ongoing, the result of this study can be fundamental base of
future analysis.
Keywords: COPD, Asian, Western
Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition
requiring therapeutic management to be tailored to the clinical characteristics
and disease severity of the individual patient.1,2 There is a need for region-
specific research and analysis of the epidemiology of COPD to raise awareness
of the disease and highlight its causes. Such information is essential for the
development of effective national health policies to ensure evidence-based
deployment of finite health care resources in the prevention and management of
COPD.3 The burden of COPD is rapidly growing in the Asia-Pacific region; Tan
et al highlighted that there were more deaths and disability suffered from COPD
in the Asian region than in developed Western countries and showed high and
varied trends of hospital admissions and mortality in various Asian countries.4,5
Poverty, high rate of smoking, pulmonary tuberculosis, air pollution, and indoor
biomass burning are traditionally huge issues in Asia.6–8 COPD phenotypes in
Asia may be somewhat different from those in Western countries.9,10 However,
there has been no definitive strategy to approach COPD patients by ethnic groups.
In this study, we compared clinical characteristics between Asian and Western
COPD patients to identify differences.
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Methods
This was a sub-analysis of an international, multicenter,
prospective cohort study. The aim of the study was to
validate the concept of clinical control in COPD.11
Eligible patients had spirometry-defined COPD (ie, post-
bronchodilator forced expiratory volume in 1 second
(FEV1)/forced vital capacity <0.7), were over 40 years of
age, and current smokers or ex-smokers with at least 10
pack-years of tobacco exposure. The prespecified criteria
of clinical control were defined by Soler-Cataluña et al.12,13
A patient was considered controlled when clinically stable
and with a low impact adjusted by level of disease sever-
ity. Impact is related to the manifestations of the disease at
the time of medical consultation and stability is related to
the changes of the clinical status of the patient over time
including the presence of exacerbations. A COPD exacer-
bation was defined as of any one of the following: acute
use of oral corticosteroids and/or a course of antibiotics,
for lower respiratory symptoms or within 5 days of an
unscheduled hospital admission/emergency department
attendance for acute respiratory symptoms. In this analy-
sis, we compared clinical characteristics between Asian
and Western COPD patients. Asian patients were enrolled
in Singapore and South Korea. Western patients were
enrolled in Spain, Poland, Ireland, the United Kingdom,
and Malta. The study was approved by the local Research
and Ethics Committees of each participating research site
(University Hospital Vall d’Hebron, Institute of
Tuberculosis and Lung Diseases, Seoul St. Mary’s
Hospital, Royal College of Surgeons, Singapore General
Hospital, Hospital de Alta Resolución de Loja, Mater Dei
Hospital, Hospital Comarcal de Laredo, Changi General
Hospital, Primary Health-care Center Son Pisà, and
Hospital Arnau de Vilanova) and all patients provided
written informed consent. Also, this study is registered in
European Network of Centres for Pharmacoepidemiology
and Pharmacovigilance (EUPAS11656) and approved by
Anonymised Data Ethics & Protocol Transparency
Committee (ADEPT0115).
Results
A total of 349 patients were analyzed. Among them, 110
(32%) patients were Asian and 239 (68%) Western. Mean
age was not significantly different; however, male sex was
more predominant in Asian than in Western (95% versus
63%, respectively; P<0.01). Body mass index
(BMI, kg/m2) was significantly lower in Asian (23.5 ver-
sus 27.1; P<0.01). Fifteen percent of Asian patients
belonged to the group with a BMI lower than 18.5, while
only 1% of Western did. Only 5% of Asian had a BMI
greater or equal to 30, while 32% of Western did. The
proportion of patients with a history of exacerbation was
lower in Asian (12% versus 64%; P<0.01). Thus, more
Asian patients were classified as Global Initiative for
Chronic Obstructive Lung Disease 2017 A or
B. However, there was no significant difference in FEV1,
COPD assessment test (CAT), Modified Medical Research
Council, chronic bronchitis phenotype, and control state
(Table 1).
Discussion
Until now, published studies that directly compared Asian
and Western COPD patients are scarce. Some of the infor-
mation about the characteristics of Asian patients came
from the analysis of patients included in randomized clin-
ical trials with strict inclusion/exclusion criteria.14,15
Moreover, previous reports only focused on the efficacy
of the drug under investigation, but not on the clinical and
epidemiological differences of participants.15,16 The cur-
rent study was observational, with relatively broad inclu-
sion criteria, which provides a more realistic overview of
the characteristics of patients in these countries. Of note,
there were some significant differences between Asian and
Western COPD patients in sex distribution, BMI, and
exacerbation history, but no differences in markers of
severity such as FEV1 (% predicted), level of control, or
CAT score.
A low rate of women in Asia could be explained by
several reasons. First, smoking rate in women is low in
Asia. According to the World Health Organization
report, smoking rate in male was 25.4% and in female
it was 4.8% in Singapore. In South Korea, it was
39.3% and 5.5%, respectively.17 Second, there could
be confounding by recruitment, as more males may
seek or are referred for treatment to the tertiary cen-
ters. Third, female COPD in Asia might be under-
detected.
There has been limited study that compared BMI
directly between different ethnicities. In this analysis,
we clearly demonstrated that the distribution of BMI
Kim et al Dovepress
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Table 1 Comparison of baseline characteristics between Asian and Western COPD patients
Asian (N=110) Western (N=239) Total (N=349) P-value
Age (years), mean (SD) 69.4 (9.1) 68.2 (8.6) 68.6 (8.8) 0.24
Sex, n (%) <0.01
Female 6 (5) 88 (37) 94 (27)
Male 104 (95) 147 (63) 251 (73)
Smoking status, n (%) 0.59
Non-smoker 0 (0) 3 (1) 3 (1)
Former smoker 83 (75) 172 (72) 255 (73)
Current smoker 27 (25) 64 (27) 91 (26)
Pack-year, median (IQR) 39 (29–60) 41 (30–61) 40 (30–60) 0.09
BMI (kg/m2), median (IQR) 23.5 (20.5–26.6) 27.1 (24.1–31.2) 26 (23–29.4) <0.01
BMI category I <0.01
≤21 kg/m2, n (%) 30 (27) 18 (8) 48 (14)
>21 kg/m2, n (%) 80 (73) 221 (92) 301 (86)
BMI category II <0.01
<18.5 kg/m2, n (%) 17 (15) 3 (1) 20 (6)
≥18.5 and <25 kg/m2, n (%) 55 (50) 75 (31) 130 (37)
≥25 and <30 kg/m2, n (%) 32 (29) 85 (36) 117 (34)
≥30 kg/m2, n (%) 6 (5) 76 (32) 82 (23)
FEV1 (%), median (IQR) 52.4 (39.3–75.1) 51.8 (39.2–63.2) 52 (39.3–65.3) 0.10
FEV1 (%), n (%) <0.01
≤35% 25 (23) 45 (19) 70 (20)
36–49% 24 (22) 60 (25) 84 (24)
50–64% 20 (18) 84 (36) 104 (30)
≥65% 41 (37) 47 (20) 88 (25)
Chronic bronchitis, n (%) 69 (63) 107 (57) 176 (59) 0.35
Asthma-COPD overlap, n (%) 9 (8) 28 (12) 37 (11) 0.31
Bronchiectasis, n (%) 15 (14) 31 (13) 46 (13) 0.85
Exacerbation <0.01
0, n (%) 96 (88) 68 (36) 164 (55)
≥1, n (%) 13 (12) 119 (64) 132 (45)
Hospital admission <0.01
0, n (%) 102 (94) 137 (73) 239 (81)
≥1, n (%) 7 (6) 50 (27) 57 (19)
mMRC, mean (SD) 1.1 (0.80) 1.55 (1.1) 1.22 (0.98) 0.10
Grade 0 8 (8) 21 (10) 29 (9)
Grade 1 63 (64) 85 (39) 148 (47)
Grade 2 19 (19) 56 (25) 75 (24)
Grade 3 8 (8) 41 (19) 49 (15)
Grade 4 0 (0) 17 (8) 17 (5)
(Continued)
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was significantly different between Asian and Western
COPD patients. BMI is an important prognostic factor
in COPD since it is included in the BODE index, which
is a powerful tool to predict mortality.18 The BODE
index is developed in Western COPD populations.
Since our data showed that BMI is lower in Asian, the
role and cut-off value of BMI in Asian might be differ-
ent. Further studies regarding BMI in Asian COPD
populations are definitely needed.
In this study, the history of exacerbation between
two groups differed significantly despite similar FEV1
and symptom severity. This could be due to differences
in management of COPD between Asian and Western
countries, or differences in type of hospital where
patients were recruited. Further studies regarding the
differences in exacerbation rate between Asian and
Western are needed.
How these differences between Asian and Western
patients affect clinical outcomes needs to be elucidated.
Since this sub-analysis was based on a prospective cohort,
we plan to analyze and compare the longitudinal outcomes
between the two groups in terms of exacerbations and
control status.
There are limitations in this study. First, Asian popula-
tion only came from two countries and their number was
much smaller. Second, it could have been better if we
made comparison with populations of other ethnic groups
and origins such as Americans and Africans. However,
Western patients in this study were enrolled in only
European countries.
Conclusion
In conclusion, predominant male gender, lower BMI,
and lower exacerbation history were characteristics of
Asian COPD patients when compared with Western. Our
study has provided unbiased real-world differences
between Asian and Western COPD patients. Since pro-
spective follow-up study is currently ongoing, the result
of this study can be fundamental base of future analysis.
How these differences between Asian and Western
patients affect clinical outcomes needs to be elucidated
in the future.
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